Navigation Links
China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
Date:11/25/2009

HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products ("ICPBP") examination for two of its new products: its Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) and its Determination Kit for Luteinizing Hormone (Colloidal Gold).

The clinical trials for both products have been completed earlier. As the examination by ICPBP is usually the last material procedure toward the final production approval for biological testing products, the Company expects to receive the final approval from the State Food and Drug Administration (SFDA) in China for the production of both products by the end of 2009. Formal production for the two new products is expected to begin in 2010.

The Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) can be used in early diagnosis of human prostate disorders, hyperplasia and cancer, because the concentration of Prostate Specific Antigen ("PSA") is an important parameter in clinical treatment of prostate related diseases.

The Determination Kit for Luteinizing Hormone (Colloidal Gold) is used in the diagnosis of female sterility. According to research by World Health Organization, 5%-8% of married couples in developed countries are suffering from the sterility. In China, sterility patients account for nearly 10% of the total population at the age of procreation. This number keeps increasing in China due to various reasons including diseases, conception control and social stress.

"We are excited to have made such great progress in the development of these new products and look forward to receiving SFDA approval for the production of both of them very soon," commented Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "We are fully committed to increasing our drug portfolio by bringing quality new products into domestic as well as international market."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-5399-4069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:     +1-646-213-1915
     Email:   crocker.coulson@ccgir.com
     Website: www.ccgirasia.com

SOURCE China Sky One Medical, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
2. China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results
3. China Medicine Announces Strong Third Quarter 2009 Results
4. Chindex International Announces Participation in Brean Murray, Carret & Co. 2009 China Growth Conference
5. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
6. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
10. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
11. China Medical Technologies to Hold its Annual General Meeting on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ALEXANDRIA, Va. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... year by the Academy of Managed Care Pharmacy ... care organizations can better address the opioid addiction ... Medication Assisted Therapies (MAT). ATAG,s newly ... in Improving Access to Naloxone," addresses many issues ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health Corporation ... Analyst Day in New York City on Thursday, December 15, 2016, beginning ... leadership team will provide an in-depth review of the ... value. The company will also discuss 2017 earnings guidance ... webcast of the event will be broadcast simultaneously on ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 02, 2016 , ... Two years ago, Arizona State University ... live by 1 million viewers and won numerous honors, including the region’s top ... the Walter Cronkite School of Journalism and Mass Communication are following up their ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
Breaking Medicine News(10 mins):